Skip to main content
. Author manuscript; available in PMC: 2014 Jul 16.
Published in final edited form as: Circulation. 2013 Jun 10;128(3):225–236. doi: 10.1161/CIRCULATIONAHA.112.000862

Figure 6.

Figure 6

AMPK kinase-dead (KD) hearts fail to demonstrate a cardioprotective action of MIF20. (A) Heart-rate-left-ventricular-developed pressure product of AMPK-KD hearts during baseline (30 min), ischemia (25 min) and post-ischemic reperfusion (30 min) after treatment with MIF20 (8 nM) or vehicle control. (n=4 hearts for each group). (B) Representative western blots comparing pACC in two representative WT and AMPK-KD hearts sampled 30 mins after post-ischemia reperfusion. Densitometry measurements (mean + SEM) are for 4 hearts in each group. *p<0.05 vs. WT vehicle. †p<0.05 vs.WT MIF20.